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Abstract
Living organisms endowed with natural benefits have been used for millions of years in
the medical practice. Seaweeds have been widely used around the world for the production
of agar and food; however, the pharmaceutical industry has drawn attention to the
activities of these natural products. In this chapter, we present some bioactive metabo‐
lites of the three phyla of seaweed (green, brown, and red algae) along with their potential
for drug development.
Keywords: Seaweeds, bioactive compounds, natural products, drug development, bi‐
oactivities
1. Introduction
The use of natural resources for medicinal purposes in the treatment and prevention of diseases
is one of the oldest practices of mankind. The earliest historical report describing the use of
natural derivatives was written and found in Nagpur, India, and is approximately 5000 years
old. These records comprise 12 recipes for drug preparation and refer to more than 250 plants
[1]. Another historical example is the book written by Emperor Shen Nung circa 2500 BC. This
Chinese book describes the use of more than 365 parts of medicinal plants; among these are
camphor, the great yellow gentian, ginseng, jimson weed, cinnamon bark, and ephedra [2]. The
Ebers Papyrus is one of the oldest and most important medical treatises known in the world.
Written in ancient Egypt, it is dated at around 1550 BC and contains more than 700 species of
plants and drugs used in therapy, such as pomegranate, castor oil, aloe, senna, garlic, onions,
figs, willow, coriander, juniper, and common centaury [3].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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and reproduction in any medium, provided the original work is properly cited.
The first initiative in the search of natural products of marine origin with pharmacological
potential began at a conference in Rhode Island, USA, under the name of “Drugs from the Sea”
in 1967. Since this important date, researchers from around the world pledged in search of
primary and secondary metabolites of various marine organisms. In 1980, the University of
Utah in the USA discovered a toxin derived from cone snail that was able to block a voltage‐
gated calcium channel. Based on the initial data, a peptide was synthesized and developed by
Elan Corporation. The FDA authorized the sale in 2004 of the first drug derived from a marine
natural product under the trade name Prialt for the treatment of chronic pain in spinal cord
injuries. In 2007, the second drug derived from marine organisms was developed. The
isoquinoline derived from the sea squirt Ecteinascidia turbinate was approved by the European
Union for the treatment of soft tissue sarcoma with the name of Trabectedin / Yondelis [4].
Even today, researchers from around the world are working to isolate, identify, and test
promising natural products derived from marine organisms to develop new drugs.
Seaweed is used extensively for development in the industries of cosmetics, fuel production,
agar production, and it also serves as animal and human food. However, due to advances in
the isolation and structural elucidation of its primary and secondary metabolites, the phar‐
maceutical industry is turning its attention toward algae. In this section, we describe the natural
products derived from seaweed, which have potential for drug development.
2. Marine seaweeds as a source of new bioactive prototypes
2.1. Green seaweeds as a source of new bioactive prototype
The primary metabolites in green seaweeds are more exploited for the development of drugs
than the secondary metabolites. Molecules such as peptides, glycolipids, and sulfated poly‐
saccharides have shown interesting results and are in an advanced phase in the drug test. As
an example, the depsipeptide Kahalalide F (KF) isolated from the mollusk Elysia rufescens that
feeds on green seaweeds of the genus Bryopsis. For isolation of the peptide, the ethanol extract
of animals was chromatographed on a silica flash column, from which the peptide mixture
was eluted with EtOAc/MeOH (1:l). A new column using high‐performance liquid chroma‐
tography (HPLC) on C18 reversed‐phase was performed, obtaining the isolation of KF. When
measuring their biological activities, KF showed IC50 values of 2.5, 0:25, and <1.0 µg/mL against
A‐549, HT‐29, and LOVO cells, respectively. Also observed was interesting antiviral activity
against Herpes simplex virus type 2 (HSV‐2) and antifungal against Aspergillus oryzae, Penicilli‐
um chrysogenum (also known as P. notatum), Trichophyton mentagrophytes, Saccharomyces
cerevisiae, and Candida albicans [5]. In 1996, five new depsipeptides (Kahalalide A‐E) were
isolated from Elysia rufescens, which feeds on green seaweed Bryopsis sp. [6]. Due to the results
obtained previously, the target for the anticancer peptide, KF, has been studied in cultured
cells. During the experiment, it was observed that the cells become swollen, due to the
formation of large vacuoles, which appeared to be the consequence of changes in lysosomal
membranes. Thus, lysosomes are a target for KF action [7]. However, over the years, other
mechanisms of action have been proposed. In 2000, KF has also shown activity against human
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prostate cancer xenografts in animal models in vivo [8]. To facilitate the advancement of studies
of anticancer activity and toxicity of KF, its synthesis was described [9]. In 2001, a stable
parenteral formulation of KF was developed, to be used in early clinical trials [10]. In 2002,
preclinical toxicity studies of KF using single‐ and multiple‐dose schedules were done in rats
[11]. In 2005, a study was initiated with the objective of determining the maximum tolerated
dose, profile of adverse events, and dose‐limiting toxicity of KF in patients with androgen
refractory prostate cancer. The study concluded that the peptide can be given safely as a one‐
hour i.v. infusion during five days at a dose of 560 µg/m2 per day once every three weeks [12].
Also in the Phase I clinical stage, another group found that the maximum tolerated dose was
800 µg/m2 to patients with advanced solid tumors [13]. Recently, a group evaluated the effect
of demographics and pathophysiologically relevant factors on KF pharmacokinetic parame‐
ters, however, no clinically relevant covariates were identified [14].
Activity‐directed isolation of the n‐hexane and dichloromethane fractions from the Capsosiphon
fulvescens resulted in obtaining three glycolipids (Capsofulvesins A‐C) of pharmacological
interest. These compounds exhibited IC50 values of 53.13 ± 2.83, 51.38 ± 0.90, and 82.54 ± 0.88
µM when measuring AChE inhibitory activity, respectively, and IC50 values of >132.28, 114.75
± 4.13, and 185.55 ± 6.95 µM in BChE assay [15]. A screening for Aldose reductase inhibitors
using the ethanol extract of 22 algae was held in South Korea. The green seaweed Capsosiphon
fulvescens had one of the best results and the fractionation of its extract also resulted in the
isolation of Capsofulvesins. Capsofulvesin A and B showed potential rat lens aldose reductase
inhibitory activity with the IC50 values of 52.53 and 101.92, respectively [16].
Also in primary metabolism, green seaweeds produce sulfated polysaccharides, which are said
to ulvans. These molecules have shown interesting immunomodulatory and anticoagulant
activities. For example, the sulfated polysaccharides of green seaweed Enteromorpha prolifera
were used to determine their in vitro and in vivo immunomodulatory activities. In vitro,
fractions rich in sulfated polysaccharides increase nitric oxide production and cytokine (TNF‐
α, IL‐6, IL‐10, and COX‐2) release in Raw 264.7 cells. In vivo, the sulfated polysaccharides
increase Con A‐induced splenocyte proliferation and IFN‐γ and IL‐2 secretions [17]. Antico‐
agulant activity of Sulfated polysaccharides of green seaweed is also disclosed in literature [18].
Among the secondary metabolites, green seaweeds synthesize mainly sterols, alkaloids, and
prenylated bromohydroquinones. Historically, the ether extract from green seaweed Cymopo‐
lia barbata has shown antibiotic and antifungal activities, but no specific compounds were
isolated. In 1976, the fractionation was carried out in the same sample, resulting in the isolation
of the first seven bromohydroquinones prenylated [19]. In 1987, another eight bromohydro‐
quinones were isolated in the same seaweed, starting the study of biological activities of these
substances [20]. A study in north coast of Puerto Rico was conducted with the green seaweed
Cymopolia barbata leading to the isolation of two bromohydroquinones guided by antimuta‐
genic assay. These compounds were active in inhibiting 2AN mutagenicity toward Salmonella
typhimurium at doses of 300, 150, and 75 µg/plate [21]. Other prenylated bromohydroquinones
have been described over the years [22]. In 2012, the green seaweed C. barbata was again
collected from Jamaica at Fairy Hill Beach and its extract prepared in dichloromethane:meth‐
anol (1:1). The fractionation of the extract resulted in the isolation of two prenylated bromo‐
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hydroquinones. The anticancer activity of both products was carried out using CCD18 Co,
HT29, HepG, and MCF‐7 cells. The compound 1 obtained IC50 values of 55.65 ± 3.28 and 19.82
± 0.46 to CCD18 Co and HT29, respectively. Compound 2 did not prove active in all tested
cells. Furthermore, the ability of compounds to inhibit the enzyme cytochrome P450 also was
evaluated. Compounds 1 and 2 showed an IC50 value of 0.93 ± 0.26 and 0.39 ± 0.05 µM,
respectively [23].
Alkaloids may be defined as a compound that has nitrogen atom(s) in a cyclic ring. In marine
algae, these substances can be classified into: a) Phenylethylamine alkaloids; b) Indole
alkaloids; or c) Other alkaloids [24]. In green seaweeds, the indole alkaloids are the main
natural products isolated. Caulerpin (3) was the first alkaloid isolated from Caulerpa genus [25]
and its isolation from the substance has shown amazing results. In India, the methanolic from
the seaweed Caulerpa racemosa was fractionated using column of silica gel (60–120 mesh) and
was eluted successively with various percentages of solvent mixtures containing petroleum
ether, chloroform, and methanol. The fractions eluted with chloroform‐petroleum ether (1: 1)
resulted in the isolation of caulerpin, which was used to evaluate the anticorrosion activity
using polarization, impedance, and atomic force microscopy assays. A protective layer on the
steel surface was observed by electrochemical impedance spectroscopy when treated with
caulerpin, demonstrating an anticorrosion effect [26].
In Brazil, caulerpin was used for investigation of their cytotoxicity on Vero cells and antiviral
activity against Herpes simplex virus type 1 (HSV‐1) KOS strain. Caulerpin demonstrated a
selectivity index better than the reference drug Acyclovir, with CC50 of 1167 µM and EC50 of
1.29 µM values. In addition, its mechanism of action was studied on the virus replication cycle.
Caulerpin seems to inhibit the alpha and beta phase of replication of HSV‐1 virus [27]. Recently,
the synthesis of Caulerpin and its analogues has been proposed along its assessment of anti‐
tuberculosis activity. All compounds exhibited activity against bacillus Mycobacterium
tuberculosis strain H37Rv. However, Caulerpin demonstrated the best IC50 value compared to
their analogues and reference drug Rifampin [28].
Steroids are triterpenic compounds having a tetracyclic system; its A, B, and C rings have six
carbons while ring D has five carbons. The vast majority of green seaweeds synthesize sterols
of 28 and 29 carbons, as an example, with one of the first compounds isolated from Codium
fragile [29]. Over the years, several sterols were isolated from green seaweeds and have shown
interesting biological activities, however, the anticancer activity is the most explored for this
type of metabolite. The green seaweed Tydemania expeditionis were collected from the Yellow
Sea in Weihai, Shandong Province of China. Its partition prepared in EtOAc was subjected to
silica gel (200–300 mesh) and eluted with cyclohexane‐acetic ether in various proportions.
Refractionation using Sephadex LH‐20 column resulted in the isolation of four sterols, which
have been used to evaluate the anticancer activity in human prostate cancer cells lines (DU145,
PC3, and LNCaP). Compound 4 exhibited inhibitory activity against the prostate cancer cells
DU145, PC3, and LNCaP with IC50 values of 12.38 ± 2.47, 2.14 ± 0.33, and 1.38 ± 0.07 µM,
respectively. Compounds 5 showed IC50 values of 31.27 ± 1.50, 40.59 ± 3:10, 19.80 ± 3.84 µM. It
was noted by researchers that the presence of hydroxyl at C‐3 increased the cytotoxic activity
of sterols, however, the presence of the hydroxyl in C‐24 diminished activity. To investigate if
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the inhibitory activities against prostate cancer cells were due to inhibition of androgen
receptor, the binding affinity of sterols was evaluated. Competitive binding assay showed that
compound 5 exhibited significant affinity to the androgen receptor with an IC50 value of 7.19
± 0.45 µM, while the compound 4 was inactive [30].
The partition prepared in EtOAc of the green seaweed Codium iyengarii, was collected from
Karachi cost of Arabian, was subjected to fractionation using silica gel and hexane, chloroform,
and methanol at binary mixture or pure, which resulted in the isolation of four sterols. The
compound 6 showed the best IC50 values when tested against Corynebacterium diptheriae,
Klebsiella pneumonia, Snigella dysentri, Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella
typhi, and Streptococcus pyogenes microorganisms [31].
Other products found less in green algae also exhibit biological activities described; for
example, bromophenols (BPs) found in Avrainvillea genre presented inhibitory activity for
HMG‐CoA reductase enzyme [32].
Figure 1. Bioactive compounds isolated from the green seaweeds.
2.2. Brown seaweeds as a source of new bioactive prototypes
Among the primary metabolites of brown seaweeds, molecules as glycolipids and sulfated
polysaccharides are used in the search for bioactivities to develop new drugs.
The brown seaweed Sargassum muticum was collected in France and its extract prepared using
organic solvent chloroform. The chloroform extract was subjected to fractionation using
column vacuum chromatography and high pressure liquid chromatography; this resulted in
the isolation of galactoglycerolipids with antibacterial activity against Shewanella putrefaciens
and Polaribacter irgensii, and antifungical activity against Pleurochrysis roscoffensis, Exanthe‐
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machrysis gayraliae, Cylindrotheca closterium, Navicula jeffreyii, Halosphaeriopsis mediosetigera,
Asteromyces cruciatus, Lulworthia uniseptata, and Monodictys pelagica [33].
The brown seaweed Lobophora variegata was collected in Mexico and its extract prepared using
dichloromethane‐methanol (7:3). The extract was dissolved in methanol‐water (9:1) and
subjected to partitioning using hexane, chloroform, ethyl acetate, and n‐butanol. The chloro‐
form fraction was subjected to column chromatography on Sephadex LH20, eluted with
hexane‐chloroform‐methanol (3:2:1), resulting in isolation of three sulfoquinovosyldiacylgly‐
cerides. The mixture of sulfoquinovosyldiacylglycerides showed activity against Entamoeba
histolytica, Trichomonas vaginalis, and Giardia intestinalis with value of IC50 of 3.9 ± 0.03 µg/mL,
8.0 ± 0.42 µg/mL, and 20.9 ± 0.89 µg/mL, respectively [34]. Other activities, such as anticancer
and inhibitor of DNA polymerase, have also been described for glycolipids [35, 36].
An experiment performed with fucoidans from the Laminaria saccharina was evaluated for its
biological activities. Fucoidans from the L. saccharina showed the inhibition of neutrophil
extravasation into peritoneal cavity in an acute peritonitis rat model at a dose of about 4
mg/kg. Anticoagulant activity was measured as the activated partial thromboplastin time
related to the heparin standard. Fucoidans the L. saccharina showed an APTT value of 33.0 ± 2
U/mg [37]. In the subsequent article, the mixture fucoidans was fractionated by ion‐exchange
chromatography that produced two differing fractions. The first fraction consisted of sulfated
fucomannoglucuronan and the second fraction consisted mainly of sulfated fucans. The
sulfated fucan showed an increased anticoagulant activity with APTT values of 29.2 ± 1.6 [38].
A study in Phase I clinical with fucans from the Laminaria japonica investigated orally admin‐
istered effects on hemostatic parameters in healthy volunteers [39].
Among the secondary metabolites, brown seaweeds synthesize different types of terpenes and
phenolic compounds. Among the diterpenes, the brown seaweeds synthesize secondary
metabolites with different carbon frameworks including dolabellane, dolastane, prenylated
guaiane diterpenes, and meroditerpenes skeletons of interest in drug development.
The brown seaweed, Dictyota pfaffii, was collected in Rocas Atoll reef, Brazil, and its extract
prepared using the mixture of organic solvents dichloromethane/methanol (7:3). This extract
was subjected to silica gel column chromatography eluted with hexane, dichloromethane,
ethyl acetate, and methanol at pure or binary mixture. The fraction eluted with dichlorome‐
thane pure and dichloromethane/ethyl acetate (9:1) resulting in compound 7, which was
recrystallized from n‐hexane and the fraction eluted with dichloromethane/ethyl acetate (6:4)
was purified using silica gel column chromatography resulting in compound 8. Compound 9
was obtained by addition of hydroxyl groups by chemical reaction. The cytotoxicity on Vero
cells and HSV‐1 antiviral activity of the compounds was evaluated. Compounds 7–9 demon‐
strate CC50 values of 185 ± 5.0, 189 ± 1.2, 184 ± 3.4 µM, and TCID50 values of 89 ± 4.5, 87 ± 3.9,
81 ± 4.1%, respectively. Compared to the drug acyclovir, the compounds demonstrated an
effective antiviral activity; however, they also showed high cytotoxicity [40]. The mechanism
of action of the compound on HSV‐1 replication cycle was studied and compound 9 inhibits
the initial events in HSV‐1 replication and decreases the levels of some early proteins of HSV‐
1, such as UL‐8, RL‐1, UL‐12, UL‐30, and UL‐9 [41]. Due to the presence of an interesting
antiviral activity, the substance Dolabelladienetriol (9) was used to inhibit human immuno‐
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deficiency virus (HIV) RT enzyme, with an IC50 value of 16.5 ± 4.3 µM. This same compound
was also used to assess their ability to inhibit HIV‐1 replication in peripheral blood mononu‐
clear cell and macrophages. Compound 9 showed an EC50 value of 8.4 µM in PBMC and 1.85
µM in macrophages. Knowing that HIV entry into cells may be mediated by various corecep‐
tor, dolabelladienetriol was used to determine its inhibition of HIV replication at different
strains. When used at a concentration of 25 µM, the compound was able to inhibit more than
80% of the replication of all strains of HIV. Tests indicate that the compound 9 can inhibit HIV‐
1 replication at a posttranscriptional step [42]. Subsequent studies demonstrated that com‐
pound 9 blocked the synthesis and integration of HIV‐1 provirus and acts as a Non‐Nucleoside
Reverse Transcriptase Inhibitors (NNRTIs) [43]. In order to develop an antiviral drug,
compound 9 was evaluated for their toxicity in vivo. Mice deaths were not observed at any
dose during the ten‐day period. Significant changes were not observed in the concentrations
of urea nitrogen, creatinine, alanine aminotransferase, uric acid, and total protein [44]. In 2014,
three news dolabellane-type diterpenoids named dolabelladienols A–C were isolated from the
brown seaweed Dictyoya pffafi. These compounds have also been shown to inhibit HIV‐1
replication in MT‐2 cells [45]. The compound Dolabelladienetriol has also proven to be effective
in the inhibition of Leishmania amazonensis replication in peripheral blood mononuclear cells
(IC50 = 43.9 µM), even in the presence of factors that exacerbate parasite growth, such as IL‐10,
TGF‐b, and HIV‐1 coinfection [46].
The brown seaweed Canistrocarpus cervicornis was collected in Rio de Janeiro, Brazil, and its
extract prepared using the organic solvent dichloromethane. This extract was subjected to
column chromatography resulting in the isolation of two dolastane diterpenes. Both diterpenes
have been shown to inhibit the activity of organ crude homogenates and purified Na+K+-
ATPase of the kidney and brain. Compound 10 showed the best results [47]. The other two
dolastane diterpenes were isolated from brown seaweed C. cervicornis and evaluated their
cytotoxicity in Vero cells and antiviral activity (HSV‐1). The compounds demonstrated a
CC50 value of 1423 and 706, and the percentage of inhibition of viral replication of 90% and
99% when used 50 µM, respectively. The position of the double bond and the hydroxyl group
seems to interfere with the cytotoxicity and antiviral activity of the substances [48]. From the
same seaweed, other dalastane diterpene was isolated from the Brazilian coast and showed
anticoagulant and antiplatelet effects [49].
The extract prepared in dichloromethane/methanol (1:1) of brown seaweed Dictyota menstru‐
alis collected on the Brazilian coast was used to evaluate its antiviral activity (HIV‐1). Through
isolation guided activity, it was possible to isolate two diterpenes prenylated guaianes. When
evaluating the antiviral activity of compounds 19 and 20 by the p24 antigen dosage in the
supernatant of PM‐1 cells, it was possible to obtain an EC50 value of 40 and 70 µM, respectively.
Both compounds showed cytotoxicity with values above 200 µM. Seeking to understand the
mechanism of action of the substances led to other tests being performed. When treated with
100 µM of the two substances, the synthesis of viral DNA was inhibited. Furthermore,
compounds 11 and 12 show IC50 values of 10 and 35 µM when evaluating their ability to inhibit
the enzyme reverse transcriptase [50]. The results obtained in the previous study investigated
the mechanism of action of two diterpenes on the enzyme reverse transcriptase. The kinetic
Seaweeds as Source of New Bioactive Prototypes
http://dx.doi.org/10.5772/62913
313
analyses of the HIV‐1 RT demonstrate that both prenylated guaianes have similar mechanisms
of inhibition of RNA‐dependent DNA‐polymerase activity, with the compound 11 being more
effective in inhibiting [51]. Subsequently, the compound 11 has also shown antiviral activity
against herpes simplex virus type 1 with CC50 value of 1000 ± 83 µM and EC50 of 1.60 ± 0.08 [52].
The brown seaweed Padina pavonia collected from the Red Sea coast in Hurghada, Egypt, was
subjected to extraction using methanol 80%, where this extract was partitioned using n‐hexane.
The n‐hexane fraction was chromatographed resulting in the isolation of two xenicane
diterpenes, which were used in the assessment of anticancer activity. Compounds 13 and 14
showed IC50 values of 13.2 µg/mL and 18.4 µg/mL in H460 cells, respectively, and IC50 values
greater than 20 µg/mL in HepG2 cells [53].
The extract prepared in dichloromethane of brown seaweed Stypopodium zonale was collected
on the coast of Tenerife, Spain and fractionated by flash chromatography. The fraction eluted
with hexane‐ethyl acetate (8:2) resulted in three meroditerpenes. Compound 15 exhibits
cytotoxic activity with IC50 values of <2.5 µg/mL in HT‐29 cells and IC50 value of 2.5 µg/mL in
H‐116 and A549 cells [54]. Meroditerpenes isolated from brown seaweed Taonia atomaria also
feature an interesting anticancer activity [55]. Meroditerpenes isolated from Stypopodium
zonale collected on the Brazilian coast showed antiviral activity [56].
Brown seaweeds also synthesize products such as phlorotannins and sesquiterpenes, which
can be used in the development of drugs. The brown seaweed Eisenia bicyclis was bought in
Japan and its extract prepared using the organic solvent Methanol. The extract was partitioned
by column system using Diaion HP‐2MG. After successive column chromatographic and
reversed‐phase HPLC, it was possible to obtain the isolation of phlorotannins. Compound 16
exhibits inhibitory activity on glycation and α‐amylase enzymes [57], the angiotensin‐
converting enzyme I inhibitory [58] and inhibits the protein tyrosine phosphatase 1B and α‐
glucosidase [59].
The brown seaweed Dictyopteris divaricata collected at the coast of Qingdao, China, was
subjected to extraction using ethanol where this extract was partitioned using ethyl acetate.
The EtOAc fraction was chromatographed resulting in the isolation of four sesquiterpenes that
were used in the evaluation of anticancer activity. These compounds have shown a moderate
anticancer activity, with IC50 values above 10 µ against several human cancer cell lines
including lung adenocarcinoma (A549), stomach cancer (BGC‐823), breast cancer (MCF‐7),
hepatocellular carcinoma (Bel7402), and colon cancer (HCT‐8) cell lines [60]. Six other sesqui‐
terpenes showed a similar IC50 value against several human cancer cell lines [61].
2.3. Red seaweeds as a source of new bioactive prototypes
Among the primary metabolites of red seaweeds, some molecules, such as glycolipids and
sulfated polysaccharides, are being used in the search for bioactivities in order to develop new
drugs.
Activity‐guided isolation of red seaweed Palmaria palmata resulted in the isolation of ten polar
lipids, among them, two sulfoquinovosyldiacylglycerides (SQDGs). The bioactive compounds
25 and 26 were demonstrated nitricoxide inhibitory activity in macrophage RAW264.7 cells
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with IC50 values of 36.5 and 11.0 µM. Moreover, the compound 26 also has been shown to
inhibit the production of nitric oxide synthase in a dose‐dependent manner [62]. Other
activities, such as antiviral (HSV‐1 and HSV‐2) and anticancer, have also been described for
glycolipids [63, 64].
Antiviral activity has been a major focus in the study of biological activities of polysaccharides
of red algae, because its polysaccharides have shown a low cytotoxicity and high efficiency
[65]. The sulfated polysaccharides of red seaweeds Sphaerococcus coronopifolius and Boergese‐
niella thyoides collected on the coast of Morocco were used in the investigation of antiviral
activity against HSV‐1 and HIV‐1. Sulfated polysaccharides were capable of inhibiting the
HSV‐1 on Vero cells with values of EC50 of 4.1 and 17.2 µg/mL, respectively. After investigation
of the mechanism of action of these substances, sulfated polysaccharides appear to inhibit viral
adsorption step of HSV‐1. The polysaccharides of S. coronopifolius prevents HIV‐induced
syncytium formation at the lowest concentration tested (12.5 µg/mL), however, the polysac‐
charides of B. thyoides did not demonstrate the same efficiency [66]. Some studies involving
the use of carrageenan are in development; for example, a Phase II trial study in the USA has
the objective of developing a vaginal gel for reducing the rate of human papilloma virus (HPV)
infection [67].
Among the secondary metabolism, red seaweeds synthesize substances of different chemical
classes such as terpenes, phenols, and acetogenins. Additionally, species of Rhodophyta are
skilled in the incorporation of chlorine and bromine atoms.
Figure 2. Bioactive compounds isolated from the brown seaweeds.
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The monoterpenes are substances with ten carbons formed by two isoprene units, and can be
cyclic or aliphatic (acyclic) [68]. Halogenated monoterpenes are found in genres Plocamium,
Portieria, and Ochtodes [69]. In general, it is believed that in the marine environment, halogen‐
ated monoterpenes serve as chemical defense in response to stressor agents, especially
herbivores. The production and storage of these metabolites must be related to the survival of
algae in the marine environment, and therefore may be potential prototypes for important
pharmacological activities [70]. An example of the activity of red algae monoterpenes was
described by Chilean researchers from studies with hexane extract of Plocamium cartilagi‐
neum collected on the coast of Antarctica. The hexane extract was subjected to column
chromatography and fractions purified by HPLC, resulting in the isolation of four cyclic
halogenated monoterpenes. One of the products 27 showed an intense insecticidal activity
against Heliothis virescens larvae and moderate activity against Spodoptera frugiperda. In the
same study, the other monoterpene 28 showed antibacterial activity, resulting in a zone of
inhibition of 19.35 mm when used to Gram‐negative bacterial strain Porphyromonas gingivalis,
a major organism responsible for chronic periodontitis [71]. Other activities of monoterpenes
belonging to Rhodophyta have been described, for example, to inhibit DNA methyltransferase
activity [72], as anticancer [73, 74], and antifungal activities [75].
Sesquiterpenes are natural products with 15 carbons, formed from three isoprene units. The
sesquiterpenes are the class of natural products more produced by phylum Rhodophyta,
especially by species of Laurencia. These secondary metabolites can have various types of
carbon skeletons, such as bisabolane, brasilane, chamigrane, cuparane, eudesmane, laurane,
and snyderane.
Halogenated sesquiterpenes with bisabolane skeleton are mainly synthesized by species
Laurencia aldingensis and Laurencia catarinensis. Recently, the in vitro production of bisabolanes
was developed through genetic engineering techniques and Saccharomyces cerevisiae metabo‐
lism [76]. This fact aroused the interest of biotechnologists, in view of the possibility of large‐
scale production. The halogenated bisabolene sesquiterpene (29) showed anthelmintic activity
against parasitant stage (L4) of Nippostrongilus brasiliensis [77].
The chamigrane sesquiterpenes exhibit a spiro ring attached to a five‐carbon ring. The chami‐
granes can be divided into: those that contain an epoxide between carbons 5 and 10 [78] and
others that do not [79]. The total synthesis of chamigrane sesquiterpene elatol was described,
which further stimulated the search for their biological activities [80], taking into account that
the elatol is the most potent known natural product with antifouling activity [81, 82]. The elatol
(30), isolated from Laurencia dendroidea, collected on the northern Rio de Janeiro coast, was
tested against the Y strain of Trypanosoma cruzi. Elatol showed a dose‐dependent effect against
the epimastigote, trypomastigote, and amastigote forms, with IC50 values of 45.4, 1.38, and 1.01
µM, respectively [83]. The elatol was also obtained from Laurencia microcladia and evaluated
for their anticancer activity in vitro and in vivo. This substance showed of IC50 1.1 µM in L929
cells and IC50 of 10.1 µM in B16F10 cells. It also caused a delay in the transition from the G1/S
phase of the cell cycle and induces apoptosis [84].
The cuparanes sesquiterpenes are rarely described in red seaweeds. The great majority of
isolates is formed by an aromatic ring attached to a ring structure of five carbon atoms and
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may or may not have double bonds in its interior. In 1996, the synthesis of Cuparene and
Cuparenol metabolites has been described from β‐cyclogeraniol [85]. Currently, these sub‐
stances are marketed, which brings a lot of interest as prototypes with biological activities.
Two cuparane sesquiterpenes (31 and 32) showed good cytotoxicity against two cell types of
lung cancer (NSCLC‐N6 and A549). This antitumor activity seems to be related to the presence
of the phenolic group and the double bond in the five‐carbon ring [86].
The eudesmane sesquiterpenes are formed by two rings of six carbons with the isopropyl
group at the carbon 7 and a bromine atom at carbon 1. Eudesmane sesquiterpenes also been
isolated from brown seaweeds, for example, from Dictyopteris divaricata [87]. In red seaweeds,
the metabolites 1‐bromoselindiene and 9‐bromoselindiene (33 and 34) were isolated species
Laurencia composita and demonstrate potent toxicity to brine shrimp [88].
The laurane sesquiterpenes are similar in chemical structure to cuparanes. These molecules
have a phenolic group attached to a cyclopentane through carbon 6, where the vast majority
has an addition of bromine to carbon 10 or 12. This metabolite class also shows the first
examples of iodinated naturally occurring substances [89]. In 2004, a major study was con‐
ducted to evaluate the antibacterial activity of secondary metabolites isolated from the genus
Laurencia. The Dibromohydroxylaurene substance (35) showed a minimum inhibitory
concentration (MIC) of 1.56 µg/mL against Streptococcus pyogenes, Moraxella catarrhalis, and
Streptococcus pneumoniae strains [90]. In Greece, 12 sesquiterpenes were isolated from red
seaweed Laurencia microcladia being investigated for anticancer activity of these metabolites.
The 7‐hydroxylaurene substance (36) showed the best results against K562, MCF7, PC3, HeLa,
A431, and CHO cells [91].
The snideranes form the second largest group of sesquiterpenes described for the algae
Laurencia genre. These sesquiterpenes are widely studied from an ecological point of view since
they are constantly being found in the digestive tract of species of mollusc Aplysia [92]. Some
biological activities have been described for 8‐Bromo‐10‐epi‐snyderol substance (37), which
showed an IC50 value of 2700 and 4000 ng/mL against strains D6 and W2 clones of Plasmodium
falciparum, respectively [93].
The brasilanes sesquiterpenes were isolated only in the species Laurencia obtuse (Hudson) JV
Lamouroux, collected on Greek Island Simi [94] and in southern Turkey [95]. Only four
brasilanes are known and their biological activities have not been explored.
The diterpenes are composed of 20 carbon atoms, which correspond to four isoprene units.
Among the known red seaweeds are more than 20 kinds of diterpene skeletons, with irieane,
labdane, and parguerane [96] being the main ones. The first irieane of red seaweeds were
isolated in 1975 from the chloroform extract of the genus Laurencia and identified by x‐ray
spectroscopy [97]. In 2010, five populations of an unidentified species of Laurencia were
collected in Malaysia for chemical research and evaluation of its antibacterial activity. The
diterpene 10‐acetoxyangasiol (38) was isolated and demonstrated an MIC of 250 µg/mL and
100 µg/mL against Staphylococcus aureus and Vibrio cholerae, respectively [98].
The labdane diterpenes are bicyclic, usually with ramification on carbon 9. Historically,
brominated diterpene Ent‐13‐epiconcinndiol was found in the specie Chondria tenuissima [99].
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However, today they are found in the genus Laurencia in great abundance [100]. Despite
already having several isolated molecules, their biological activities have been little explored.
The parguerane diterpenes are formed by a tricyclic structure with six carbons in each cycle.
All described skeletons have a standard addition of the bromine atom at carbon 15. The vast
majority of pargueranes was isolated from red algae, and has a double bond between carbons
9 and 11 with the addition of a hydroxyl group on carbon 16. In a study from Theuri Island,
Japan, the isolation of parguerane-type diterpenes was performed and its anticancer activity
was tested in P388 and HeLa cells. The monoacetate parguerane diterpene showed the best
results with IC50 values of 0.3 and 1.1 µg/mL for HeLa and P388 cells, respectively. The acetoxy
group at C2 and bromine at C15 are important for anticancer activity [101].
The triterpenes have 30 carbons in their structure and are derived from six isoprene units [102].
Over 20,000 triterpenoids were isolated and identified in nature, where their structures can be
classified into different chemical skeletons, such as squalene, lanostane, dammarane, lupane,
oleanane, ursane, and others [103].
The halogenated triterpenoids found in red seaweeds are the type squalene and are known to
exhibit excellent anticancer activity. As an example, we can highlight the triterpenoid isolated
from red seaweed Laurencia mariannensis collected in China. This compound exhibited
significant cytotoxic activity against cancer cells P‐388, with CC50 value of 0.6 µg/mL [104]. In
order to obtain products with biological activity, synthesis of some halogenated triterpenes
have been proposed, for example, the synthesis of Thyrsiferol (39) [105]. Using low concen‐
trations of this product (3 µM), we observed 60% inhibition of Hypoxia‐inducible factors‐1 in
T47D human breast cancer cells. Furthermore, the same natural product has been shown to
inhibit the production of messenger RNA of VEGF and GLUT‐1 [106].
The acetogenins are derived from the metabolism of fatty acids. The first acetogenin halogen‐
ated C15 of red seaweed was isolated from the methanol extract of seaweed Laurencia glandu‐
lifera [107]. Halogenated aromatic polyketides can be classified as linear or cyclic, where the
ring of the cyclic metabolites can range from five to twelve atoms in their structure [108]. On
the coast of Spain, Laurencia marilzae was collected in the intertidal zone for chemical and
biological research evaluation. Its extract was obtained in CH2Cl2/MeOH (1: 1) and subjected
to column chromatography using Sephadex and HPLC chromatography. The linear acetoge‐
nin Adrienyne (Figure 6A) and its isomer were isolated. The biological activity was tested
using the A2780 cell line, HBL‐100, HeLa, SW1573, T‐47D, and WiDr. After the incubation
period, the substance showed CC50 greater than 10 µg/mL [108]. Acetogenins cyclic halogen‐
ated also have anticancer activity described in the literature [109].
The BPs are substances formed by one or more benzene rings linked to at least one bromine
atom. The first BPs isolated from marine organisms were found in red seaweed Rhodomela
larix [110]. The BPs are known to have various biological activities [111]. The BPs isolated from
the polar extract (MeOH:H2O ‐ 95:5) of Rhodomela confervoides, collected off the coast of China
were tested against strains of Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli,
and Pseudomonas aeruginosa. The ether 2,3‐dibromo‐4,5‐dihydroxybenzyl ether (41) showed the
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Figure 3. Bioactive compounds isolated from the red seaweeds.
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best results [112]. Inhibiting the activity of the enzyme Glucose‐6‐phosphate dehydrogenase
also was described by BPs [113].
3. Conclusion
Based on the work described in this chapter, it is clear that seaweed is endowed with a variety
of structurally and chemically diverse metabolites having a broad spectrum of biological
activities. Of all natural products presented, KF peptide from green seaweed appears to be the
most promising in the development of a new drug, since it has excellent biological activity and
a known synthesis pathway. We also believe that Dolabelladienetriol, a dolabellane diterpene
isolated from Dictyota pfaffii, can be used as an antiviral drug in the future.
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